Kelly Financial Services’s Teva Pharmaceuticals TEVA Stock Holding History

Kelly Financial Services’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-140	Closed	-$1.05K	–	782
2023 Q2	$1.05K	Hold	140	–	–	﹤0.01%	601
2023 Q1	$1.24K	Hold	140	–	–	﹤0.01%	568
2022 Q4	$1.28K	Hold	140	–	–	﹤0.01%	546
2022 Q3	$1.13K	Hold	140	–	–	﹤0.01%	561
2022 Q2	$1.05K	Hold	140	–	–	﹤0.01%	554
2022 Q1	$1.31K	Hold	140	–	–	﹤0.01%	557
2021 Q4	$1.12K	Hold	140	–	–	﹤0.01%	580
2021 Q3	$1.36K	Sell	140 -1,246	-90%	-$11.7K	﹤0.01%	556
2021 Q2	$140K	Buy	1,386 +1,246	+890%	+$13.2K	0.01%	337
2021 Q1	$1.62K	Hold	140	–	–	﹤0.01%	524
2020 Q4	$1.35K	Sell	140 -10	-7%	-$96	﹤0.01%	492
2020 Q3	$1.35K	Hold	150	–	–	﹤0.01%	460
2020 Q2	$1.85K	Hold	150	–	–	﹤0.01%	439
2020 Q1	$1.35K	Hold	150	–	–	﹤0.01%	426
2019 Q4	$1.47K	Hold	150	–	–	﹤0.01%	446
2019 Q3	$1.03K	Hold	150	–	–	﹤0.01%	454
2019 Q2	$1.39K	Hold	150	–	–	﹤0.01%	403
2019 Q1	$2.35K	Buy	+150	New	+$2.65K	﹤0.01%	360

Other funds holding TEVA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

IAM

Ion Asset Management Herzliya, Israel $911M AUM 24.97% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Kelly Financial Services's TEVA Position: Q3 2023 in Review

Kelly Financial Services sold out of Teva Pharmaceuticals (TEVA) in Q3 2023, closing a stake of 140 shares — an estimated $1.05K sold.

Kelly Financial Services first reported a position in TEVA in Q1 2019 and held it in 18 quarters. The position peaked at $140K in Q2 2021. 435 funds tracked by Wall St. Rank hold TEVA as of Q3 2023.

Kelly Financial Services reported no remaining Teva Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Kelly Financial Services sold 140 Teva Pharmaceuticals shares in Q3 2023, an estimated $1.05K.
Kelly Financial Services first reported a position in Teva Pharmaceuticals in Q1 2019 and held it in 18 quarters.
Kelly Financial Services's Teva Pharmaceuticals position peaked at $140K in Q2 2021.
435 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2023.

Based on Kelly Financial Services's 13F filing for Q3 2023, filed 17 Jul 2024.